Robert Armstrong, PhD
Robert Armstrong, PhD, is the Chief Executive Officer and Co-Founder of Boston Pharmaceuticals, a clinical-stage biopharmaceutical company developing differentiated therapeutics co-founded by Dr. Armstrong and Chris Viehbacher, the current Executive Chairman of Boston Pharmaceuticals, Managing Partner of Gurnet Point Capital, and former head of Sanofi.
With over 20 years of experience working in research and development in the biopharmaceutical industry, Dr. Armstrong has been involved in the discovery and clinical development of programs across multiple disease areas.
Dr. Armstrong created and led the small-molecule R&D organization at Amgen in Thousand Oaks, California. He subsequently co-led research at Eli Lilly and Company as Vice President of Global Medicinal Chemistry, was head of the company’s translational medicine group, Chorus, and was Vice President of Global External R&D. He served on the finance and scientific advisory boards of Lilly BioVentures.
Prior to working in industry, he was a tenured professor of chemistry and biochemistry at the University of California at Los Angeles. He received his BS in chemistry at the University of California San Diego, his PhD in chemistry from Colorado State University, and was a National Institutes of Health (NIH) postdoctoral fellow at Harvard University.